Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Weight Loss Drugs Efficacy Studies Mental Health HIV Prevention Cancer Treatment Competition Phase 3 Ketamine Weight-Loss Drugs Drug Safety Oncology Treatments Patient Safety PrEP Mpox Treatment Puberty Blockers Depression Treatments Multiple Myeloma Diabetes Treatment Neurological Conditions Drug Approval Drug Supply New Chemical Entities ALS Regulatory Approval Weight Loss Treatments Drug Efficacy Weight Management Sanofi Phase 2 Trials Psychedelic Research Chronic Conditions Phase 2 Pulmonary Arterial Hypertension Metabolic Diseases Rare Diseases Pulmonary Sarcoidosis HARMONi Trials Response Rate Drug Effectiveness Phase 3 Trials Semaglutide Candidates GLP-1s

Viking Therapeutics Jumps After Wider Q3 Loss as R&D Ramp Signals Obesity-Drug Progress

Phase 3 progress for an obesity shot, with plans for an amylin IND filing, drew buying interest that lifted shares about 11%.

Quoin Pharmaceuticals Shares Jump on $104.5 Million Private Placement With $16.8 Million Upfront